pharmaphorum mediaSummit enters biomarker collaboration for rare disease, Duchenne Muscular DystrophySummitSummit
Summit enters biomarker collaboration for rare disease, Duchenne Muscular Dystrophy
Monday, February 11, 2013Summit · Online
About this event
Summit has entered into a rare disease biomarkers collaboration, supported by a grant from the Foundation to Eradicate Duchenne. A UK drug discovery company has teamed up with Dr Yetrib Hathout from the Washington DC Children’s. Summit enters biomarker collaboration for rare disease, Duchenne Muscular Dystrophy is an official summit listing associated with pharmaphorum media.
